Alkermes Plc (ALKS) Stake Decreased by UBS Asset Management Americas Inc.

UBS Asset Management Americas Inc. trimmed its position in shares of Alkermes Plc (NASDAQ:ALKS) by 4.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,212,063 shares of the company’s stock after selling 51,046 shares during the quarter. UBS Asset Management Americas Inc. owned 0.79% of Alkermes worth $66,336,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Toronto Dominion Bank boosted its position in shares of Alkermes by 12.7% during the second quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock worth $109,000 after purchasing an additional 212 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Alkermes by 7.6% during the second quarter. The Manufacturers Life Insurance Company now owns 5,804 shares of the company’s stock worth $336,000 after purchasing an additional 409 shares in the last quarter. CIBC Asset Management Inc lifted its position in Alkermes by 12.6% in the 4th quarter. CIBC Asset Management Inc now owns 7,287 shares of the company’s stock valued at $399,000 after acquiring an additional 818 shares in the last quarter. Public Employees Retirement Association of Colorado lifted its position in Alkermes by 3.2% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 31,504 shares of the company’s stock valued at $1,724,000 after acquiring an additional 970 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Alkermes by 4.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,855 shares of the company’s stock valued at $1,908,000 after acquiring an additional 1,462 shares in the last quarter.

Shares of Alkermes Plc (NASDAQ ALKS) opened at $58.60 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.78 and a quick ratio of 2.72. Alkermes Plc has a 52 week low of $46.42 and a 52 week high of $71.22.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Wednesday, February 14th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.32. Alkermes had a negative net margin of 17.48% and a negative return on equity of 4.32%. The firm had revenue of $275.37 million for the quarter, compared to analyst estimates of $251.23 million. During the same period in the previous year, the business earned $0.02 EPS. The company’s revenue was up 29.0% compared to the same quarter last year. analysts forecast that Alkermes Plc will post -0.8 EPS for the current year.

In other Alkermes news, SVP James M. Frates sold 20,932 shares of Alkermes stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $50.51, for a total value of $1,057,275.32. Following the sale, the senior vice president now directly owns 164,971 shares in the company, valued at approximately $8,332,685.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Iain Michael Brown sold 10,652 shares of Alkermes stock in a transaction on Friday, December 29th. The shares were sold at an average price of $54.81, for a total transaction of $583,836.12. The disclosure for this sale can be found here. Insiders sold a total of 146,365 shares of company stock worth $8,994,542 over the last quarter. Company insiders own 5.34% of the company’s stock.

ALKS has been the topic of several research reports. ValuEngine raised shares of Alkermes from a “sell” rating to a “hold” rating in a research report on Friday, December 1st. Credit Suisse Group boosted their price objective on shares of Alkermes from $66.00 to $70.00 and gave the company an “outperform” rating in a research report on Friday, February 16th. Jefferies Group cut shares of Alkermes from a “buy” rating to a “hold” rating and boosted their price objective for the company from $63.19 to $66.00 in a research report on Thursday. BidaskClub cut shares of Alkermes from a “hold” rating to a “sell” rating in a research report on Saturday, January 20th. Finally, Zacks Investment Research raised shares of Alkermes from a “hold” rating to a “buy” rating and set a $71.00 price objective on the stock in a research report on Monday, February 5th. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $64.58.

COPYRIGHT VIOLATION NOTICE: “Alkermes Plc (ALKS) Stake Decreased by UBS Asset Management Americas Inc.” was reported by Week Herald and is the property of of Week Herald. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://weekherald.com/2018/02/24/alkermes-plc-alks-stake-decreased-by-ubs-asset-management-americas-inc.html.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply